InformationClinical trials have complex eligibility criteria.
Always talk to your clinician about you’re interest in participating in a trial.
Learn why

Optimise reading forHealth ProfessionalsPatients

Closed (no longer recruiting)Last updated: 31 January 2024

BIOMEDE: This phase II trial is testing three oral drugs (Erlotinib, Everolimus and Dasatinib) as a possible treatment for Diffuse Intrinsic Pontine Glioma (DIPG)Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication

Clinical summary

Summary

Participants in this study will be allocated to a treatment that specifically targets a biological abnormality identified via a biopsy. The possible treatment groups are as follows; (1)If the tumor overexpresses EGFR without PTEN loss of expression, patients may receive erlotinib or dasatinib allocated by randomization; (2) If the tumor shows loss of PTEN expression without EGFR overexpression, patients may receive everolimus or dasatinib allocated by randomisation; (3) If the tumor shows both EGFR overexpression and loss of PTEN expression, patients may receive erlotinib, everolimus or dasatinib by randomisation; (4) If the tumor shows neither EGFR overexpression nor loss of PTEN expression (a very rare situation in our experience), patients will receive dasatinib; (5) If the biopsy assessment is not contributive, the treatment will be allocated by randomisation between erlotinib, everolimus and dasatinib.

Conditions

This trial is treating patients with Diffuse Intrinsic Pontine Glioma (DIPG).

Cancer

Brain and Spinal Cancers Brain and Spinal

Age

People0 - 25

Phase

II

Trial Acronym

BIOMEDE

More information

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Trial sponsor

Innovative Therapies For Children with Cancer Consortium, Institut Gustave Roussy

Scientific Title

Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication

Eligibility

Inclusion

Eligibility criteria for the BIOMEDE study (pre-screening for the randomised subtrials)

  • Diagnosis of DIPG (clinical and radiological, or histological in case the biopsy was performed before study entry)
  • DIPG at diagnosis: no prior chemotherapy for the present cancer;no prior cerebral radiation therapy
  • NB : Metastatic disease allowed. Patient with metastatic disease are eligible for the study (including the randomised trial if diagnosis of DIPG confirmed). In this situation, radiotherapy will have to start within three weeks after the biopsy while targerted treatment will start at the end of the irradiation.
  • Age > 6 months and < 25 years. For children below the age of 3 years, inclusion in the study and medical decisions should be discussed with the coordinating investigator.
  • Eligible for a biopsy, or biopsy performed for diagnostic purpose and material available for the biomarker assessment
  • Eligible for cerebral radiotherapy
  • Patient covered by an health insurance if national requirement
  • Written informed consent given by patient and/or parents/legal representative for biomarkers assessment and registration in the study.

Common eligibility criteria for the BIOMEDE randomised subtrials

  • Eligibility criteria for the study (see above)
  • Confirmed histological diagnosis of diffuse intrinsic pontine glioma (grade II, III, IV WHO), confirmed by central pathology review (including the assessment of the loss of H3K27me3 by immunohistochemistry or the presence of a mutation in the histone H3 variant genes).

Patients without classical clinical and radiological diagnostic criteria who fulfil the histological and biological criteria of DIPG are eligible for the trial.

Pilocytic astrocytoma and gangliogliomas are not eligible.

  • Life expectancy > 12 weeks after the start of study treatment
  • Karnofsky performance status scale or Lansky Play Scale > 50%. The PS should not take the neurologic deficit per se into account. NB: Children and young adults with a worse performance status due to glioma-related motor paresis can be included.
  • Absolute neutrophil count > 1.5 x 109/l, Platelets > 100 x 109/l
  • Total bilirubin < 1,5 x ULN, AST and ALT< 2,5 x ULN
  • Serum creatinine < 1,5 X ULN for age. If serum creatinine > 1,5 ULN, creatinine clearance must be > 70 ml/min/1,73 m² (EDTA radioisotope GFR or 24 hours urines collection)
  • Normal coagulation tests: prothrombin rate (prothrombin time = PT), TCA (PTT), fibrinogen
  • No current organ toxicity > grade 2 according to the NCI-CTCAE version 4.0 especially cardiovascular, pulmonary or renal disease (,including but not limited to: congenital long QT syndrome, nephrotic syndrome, glomerulopathy, uncontrolled high blood pressure despite adequate treatment, interstitial lung disease, pulmonary arterial hypertension). In case of known or possible cardiac disease, a cardiological advice will be required prior to the inclusion in the randomized trial as a preexisting cardiopathy represents a contra-indication to dasatinib.
  • Effective contraception for patients (male and female) of reproductive potential during their entire participation in the study and during 6 months after the end of treatment
  • Negative pregnancy test (serum beta-HCG) evaluated in the last week in females of reproductive potential
  • Written informed consent given by patient and/or parents/legal representative for treatment and randomization

Eligibility criteria for the subtrials Eligibility criteria for the different subtrials will be mainly based on biomarkers assessment as detailed in the table above. In addition, contra-indication and precautions for use to specific drugs will be considered.

Exclusion

Non eligibility criteria for the study

  • Massive intratumour bleeding
  • Any other concomitant anti-cancer treatment not foreseen by this protocol
  • Any other cancer during the last 5 years
  • Uncontrolled intercurrent illness or active infection
  • Any other co-morbid condition that in the investigator's opinion would impair study participation
  • Unable for medical follow-up (geographic, social or mental reasons)
  • Patient not fulfilling one of the previous eligibility criteria.
  • Patient previously treated with irradiation on the brainstem for another neoplasm
  • Patient with congenital galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption.
  • Patient not covered by a social security agreement accepted in the treating country if national requirement
  • Pregnant or breast feeding women
  • NB: A patient with known hypersensitivity for one the drug or its excipients could still participate to the study and receive one of the other drug(s)

Inclusion

  • You have been diagnosed with cancer, but have not received any treatment.

Exclusion

  • You have been diagnosed with a prior or secondary type of cancer.
  • You have certain types of non-cancer medical conditions.
  • You have had certain treatments, surgical procedures or drugs.
Message

Clinical trials have complex eligibility criteria.

Ask your doctor if this trial could be right for you.

Participating hospitals

+ Show non-recruiting hospitals

Closed hospitals

Completed hospitals

InformationTell us if you find this trial availability is not accurate.Report inaccuracy

Get Support

Example

Cancer Connect

Speak with someone who has cancer clinical trial experience.

Learn more

Example

Cancer Council’s cancer nurses

If you need cancer information and practical support for yourself, a carer, family or friend, contact Cancer Council’s experienced cancer nurses on 131120.

Learn more

Example

Information for family, friends and carers

When you are considering a cancer clinical trial, it is a good idea to discuss it with your family, friends or carers.

Learn more

Victorian Cancer Registry Victorian Government

The Victorian Cancer Trials Link is supported by the Victorian Government through the Victorian Cancer Agency.

RAP

Cancer Council Victoria would like to acknowledge the traditional custodians of the land on which we live and work. We would also like to pay respect to the elders past and present and extend that respect to all other Aboriginal people.